The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study

INTRODUCTION: Brentuximab vedotin (BV) showed high overall remission rates in refractory/relapsed classical Hodgkin’s lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Although the efficacy of BV has been reported in clinical trials, its efficacy as a frontline therapy in real world...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Xiaomeng, Guo, Wei, Wang, Yinping, Li, Jia, Zhao, Yangzhi, Qu, Limei, Yan, Xu, Li, Junna, Guo, Qiang, Young, Ken. H., Bai, Ou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799538/
https://www.ncbi.nlm.nih.gov/pubmed/34797505
http://dx.doi.org/10.1007/s12325-021-01943-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799538/
https://www.ncbi.nlm.nih.gov/pubmed/34797505
http://dx.doi.org/10.1007/s12325-021-01943-z

Ejemplares similares